
USA - NASDAQ:GHDX -
The current stock price of GHDX is 63.44 null. In the past month the price decreased by -6.57%. In the past year, price decreased by -22.32%.
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.
GENOMIC HEALTH INC
301 PENOBSCOT DRIVE
REDWOOD CITY CA 94063
CEO: Kimberly J. Popovits
Phone: 650-556-9300
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.
The current stock price of GHDX is 63.44 null. The price decreased by -0.69% in the last trading session.
GHDX does not pay a dividend.
GHDX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
GHDX stock is listed on the Nasdaq exchange.
ChartMill assigns a fundamental rating of 5 / 10 to GHDX. GHDX has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months GHDX reported a non-GAAP Earnings per Share(EPS) of 1.4300000000000002. The EPS increased by 186% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.81% | ||
| ROA | 12.29% | ||
| ROE | 16.2% | ||
| Debt/Equity | 0.15 |